# Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb

Source: https://onco.cc/trials/nct03486873/  
OnCo record `nct03486873` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Favezelimab run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) is a phase 3 interventional study registered as NCT03486873 by Merck Sharp & Dohme LLC, with 3500 participants planned, started 2018-08-21. Conditions listed: Solid Tumors, Hematologic Malignancies. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03486873
- Phase: 3
- Setting: A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 3500

## Sources

- ClinicalTrials.gov NCT03486873: https://clinicaltrials.gov/study/NCT03486873

## Connected records

- drugs: [Favezelimab](https://onco.cc/drugs/favezelimab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct03486873.json